FDA approves upgraded version of Moderna, Pfizer vaccines for certain populations

　　The U.
S.
Food and Drug Administration on August 31 revised the emergency use authorization for Moderna and Pfizer’s new crown vaccines, approving certain age groups to receive upgraded versions of these two vaccines as booster shots to provide for the Omicron variant.
better protection
.
The U.
S.
Food and Drug Administration said in a statement that the upgraded vaccine is a bivalent vaccine that targets the original strain of the new coronavirus as well as the new subtypes BA.
4 and BA.
5 of the new coronavirus Omicron variant.
role
.
According to the FDA authorization, the public can receive the upgraded version of Moderna or Pfizer vaccine as a single booster dose at least two months after the completion of the initial vaccination or booster dose
.
The upgraded version of the Moderna vaccine is suitable for people 18 years of age and older, and the upgraded version of the Pfizer vaccine is suitable for people 12 years of age and older
.
The FDA said that the new subtypes BA.
4 and BA.
5 are currently the dominant strains in the United States, and the two new subtypes are expected to continue to spread this fall and winter
.
FDA Commissioner Robert Califf said in a statement that public indoor activity time will increase after entering the fall, and it is strongly recommended that eligible members of the public receive upgraded vaccines to better protect against currently circulating mutant strains
.